At Moderna, OpenAI’s GPTs are changing almost everything
Moderna is expected to announce a partnership Wednesday with artificial-intelligence heavyweight OpenAI, a deal that aims to automate nearly every business process at the biotechnology company and boost the ChatGPT maker’s reach into the enterprise. As part of the transaction, some 3,000 Moderna employees will have access to ChatGPT Enterprise, built on OpenAI’s most advanced language model, GPT-4, by the end of this week. Further integration of AI into more of its processes could help Moderna outpace its plan to roll out 15 new products within the next five years, the Cambridge, Mass., company said.
Terms of the deal weren’t disclosed. “Eventually, AI will be able to do more and more science. But the best way to get there is to enhance the productivity of people and accelerate what they can do," said OpenAI Chief Executive Sam Altman about Moderna’s AI push.
Moderna is looking to move beyond Covid, using its messenger RNA platform on a variety of fronts, from preventing viral illnesses to treating cancer. CEO Stéphane Bancel called the OpenAI partnership, and its use of AI in general, key to helping the vaccine maker transform every business process: “How do we use it at scale to reinvent all of Moderna’s business processes, in science, in legal, in manufacturing—everywhere." So far, Moderna employees have created over 750 unique, tailored versions of OpenAI’s ChatGPT, also known as GPTs, that are designed to facilitate specific tasks or processes across the business. Some of these GPTs help select the optimal doses for clinical trials and help draft responses to questions from regulators.
Read more on livemint.com
